Predicine, Inc.
Predicine, Inc., a leading player in the precision medicine industry, is headquartered in the United States, with significant operations across key regions globally. Founded in 2015, the company has rapidly established itself as a pioneer in genomic profiling and liquid biopsy technologies, focusing on oncology and other critical health areas. Predicine's core offerings include advanced genomic testing services and innovative biomarker solutions that enable personalised treatment strategies for cancer patients. What sets Predicine apart is its commitment to integrating comprehensive genomic data with clinical insights, enhancing the accuracy of diagnostics and therapeutic decisions. With a strong market position, Predicine has achieved notable milestones, including collaborations with major pharmaceutical companies and contributions to groundbreaking research in cancer treatment. The company continues to drive advancements in precision medicine, making significant strides in improving patient outcomes.
DitchCarbon Score
How does Predicine, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Predicine, Inc.'s score of 18 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Predicine, Inc.'s reported carbon emissions
Predicine, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in their latest emissions report. Consequently, there are no recorded emissions in terms of Scope 1, 2, or 3, nor are there any documented reduction targets or climate pledges. As of now, Predicine has not established any publicly available climate commitments or initiatives aimed at reducing carbon emissions. This lack of data suggests that the company may still be in the early stages of developing a comprehensive sustainability strategy or may not yet have formalised its climate action plans. In the context of the industry, many organisations are increasingly adopting science-based targets and committing to net-zero emissions, highlighting the importance of transparency and accountability in climate action. Predicine's current position may reflect a broader trend among emerging companies in the biotechnology sector, where establishing robust environmental practices is becoming essential for long-term viability and stakeholder trust.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Predicine, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
